Skip to content
Back to Blog
Bio
2026-03-247 min read26

$150B GLP-1 Obesity Drug Market — SME Bio Entry Strategy & Government Support Utilization

A strategic guide for Korean SME biotech companies to enter the $150B GLP-1 obesity drug market through formulation innovation, multi-mechanism drug development, and CDMO services, with actionable roadmaps for leveraging government R&D programs including the National New Drug Development Program and Bio-Health Innovation Fund.

KITIM Consulting Team

GLP-1 Obesity Drug Global Market Overview and 2026 Outlook

The GLP-1 (glucagon-like peptide-1) receptor agonist-based obesity therapeutics market is experiencing unprecedented growth. Goldman Sachs projects the global obesity drug market will reach $150 billion by 2035, while Morgan Stanley forecasts a compound annual growth rate (CAGR) exceeding 20%.

As of 2025, Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide) command roughly 80% of the market in a duopoly structure. However, persistent supply shortages and high annual treatment costs (exceeding $12,000) present clear opportunities for challengers. Global pharma giants including Pfizer, Roche, and Amgen, as well as Korean companies such as Hanmi Pharmaceutical and Yuhan Corporation, are aggressively building next-generation GLP-1 pipelines.

Differentiated Market Entry Strategies for Korean SME Biotech

Targeting Unmet Needs Through Formulation Innovation

Most approved GLP-1 obesity treatments currently require once-weekly subcutaneous injections. Formulation differentiation—including oral formulations, microneedle patches, and long-acting monthly injectables—represents a core strategy for SMEs to enter the market without directly competing against big pharma. Given that oral semaglutide (Rybelsus) has a bioavailability below 1%, drug delivery systems (DDS) that dramatically improve absorption rates hold significant licensing value.

Next-Generation Multi-Mechanism Drug Development

Combination-mechanism drugs addressing the key limitation of GLP-1 monotherapy—muscle mass loss (25–40% of weight lost comes from lean mass)—are emerging as next-generation blockbuster candidates. Triple agonists targeting GLP-1/GIP/glucagon, activin receptor blockers for muscle preservation, and amylin analog combinations that simultaneously improve metabolic function and preserve muscle offer SMEs a meaningful area for research differentiation.

Entering the Supply Chain via CDMO Services

The global surge in GLP-1 demand has driven rapid growth in the peptide CDMO (contract development and manufacturing organization) market. Beyond major biosimilar manufacturers like Samsung Biologics and Celltrion, SMEs with specialized peptide synthesis and purification capabilities have expanding opportunities to participate as GLP-1 active pharmaceutical ingredient (API) supply partners. This path offers lower initial investment requirements compared to novel drug development and enables stable revenue generation.

Leveraging Government R&D Support Programs

Bio-Dedicated Funds and National Drug Development Programs

The Korean government has designated the bio-pharmaceutical industry as a national strategic technology sector and operates substantial support frameworks.

  • National New Drug Development Program: Up to KRW 10 billion (approx. $7.5M) in funding from candidate discovery through Phase 2 clinical trials, with priority consideration for GLP-1-related obesity and metabolic disease projects
  • Pan-Ministerial Medical Device Program: Development projects for drug delivery devices such as microneedle patches
  • Bio-Health Innovation Fund: A KRW 2 trillion (approx. $1.5B) public-private fund, available for investment in companies with obesity drug pipelines
  • TIPS and TIPS Deep Tech: R&D funding plus commercialization support for early-stage biotech startups
  • Government Support Roadmap from Clinical Trials to Approval

  • Preclinical Stage: Collaborate with KRICT for drug candidate synthesis and optimization; seek pre-consultation with MFDS on preclinical studies
  • Phase 1–2 Clinical Trials: Clinical design consulting through KoNECT; government matching of up to 70% of clinical trial costs
  • Global Expansion: KOTRA bio overseas expansion programs; exhibition support for BIO USA and CPhI
  • Approval and Certification: MFDS fast-track designation eligibility for obesity as an unmet medical need; preliminary review for priority assessment
  • Risk Management and KITIM Consulting Support

    Entering the GLP-1 obesity drug market involves substantial risks including patent barriers, regulatory uncertainty, and significant clinical trial costs.

  • Patent Strategy: Analysis of Novo Nordisk and Lilly core patent expiration timelines (early 2030s); design-around strategies for formulation and dosing patents
  • Regulatory Response: Dual FDA-MFDS approval strategies; monitoring of obesity drug reimbursement trends
  • Investment Attraction: Technology assessment (TSA) preparation; pipeline valuation for technology-based special listing requirements
  • KITIM (Korea Institute of Technology Innovation Management) provides comprehensive support for SME biotech companies, including government R&D proposal development, strategic planning for programs such as the National New Drug Development Program and TIPS, and stage-by-stage government support roadmap design for clinical development. If you need tailored consulting for GLP-1 obesity drug market entry, please reach out through our [Contact Page](/contact) to schedule a consultation.

    GLP-1 Obesity DrugObesity Drug MarketBio SME StrategyOral GLP-1Government R&D Support

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.